J Int Med Res. 2021 Apr;49(4):3000605211005945. doi: 10.1177/03000605211005945.
ABSTRACT
OBJECTIVE: To evaluate the efficacy and safety of bicyclol in patients with drug-induced liver injury (DILI) using a nationwide database.
METHODS: We retrospectively analyzed the clinical data of DILI patients in the DILI-R database. Propensity score matching was performed to balance the bicyclol and control groups, and alanine aminotransferase (ALT) recovery was compared between the two groups. Factors associated with ALT recovery and safety were identified.
RESULTS: The analysis included the data of 25,927 patients. Eighty-seven cases were included in the bicyclol group, with 932 cases in the control group. One-to-one propensity score matching created 86 matched pairs. The ALT normalization rate in the bicyclol group was significantly higher than that in the control group (50.00% vs. 24.42%), and statistical significance was found in the superiority test. After adjustment of baseline ALT levels, baseline total bilirubin levels, sex, age, acute or chronic liver diseases, and suspected drugs in the multivariate logic regression analysis, the major influencing factors for ALT recovery included the time interval between ALT tests (days) and the group factor (bicyclol treatment). There were no differences in the proportion of renal function impairment or blood abnormalities between the two groups.
CONCLUSIONS: Bicyclol is a potential candidate for DILI.
PMID:33853430 | DOI:10.1177/03000605211005945